IDERA PHARMACEUTICALS, INC. Uncategorized Contracts & Agreements
41 Contracts & Agreements
- Description of the Aceragen, Inc. Securities Registered Under Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on April 13, 2023)
- Project Agreement No. 01, by and between Advanced Technology International and Arrevus, Inc., dated August 24, 2021 (Filed With SEC on November 14, 2022)
- Base Agreement, by and between Advanced Technology International and Arrevus, Inc., dated May 28, 2021 (Filed With SEC on November 14, 2022)
- Letter Agreement by and among Dan Salain and Aceragen, Inc., dated February 25, 2021 (Filed With SEC on September 30, 2022)
- Letter Agreement by and among John Taylor and Aceragen, Inc., dated February 25, 2021 (Filed With SEC on September 30, 2022)
- Description of the Idera Pharmaceuticals, Inc. Securities Registered Under Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 1, 2021)
- Description of the Idera Pharmaceuticals, Inc. Securities Registered Under Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 12, 2020)
- Scientific Advisor Agreement effective June 1, 2017 by and between Idera Pharmaceuticals, Inc. and Sudhir Agrawal (Filed With SEC on March 7, 2018)
- 167 Sidney Street Renewal LOI Idera Pharmaceuticals September 20, 2016 (Filed With SEC on March 15, 2017)
- Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions (Filed With SEC on March 15, 2017)
- EXHIBIT A Definitions (Filed With SEC on May 9, 2016)
- EXHIBIT A Definitions (Filed With SEC on August 6, 2015)
- EXHIBIT A Definitions (Filed With SEC on May 11, 2015)
- Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. (Filed With SEC on August 12, 2014)
- Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. (Filed With SEC on August 12, 2014)
- RESTATED CERTIFICATE OFINCORPORATION OF HYBRIDON,INC. (Filed With SEC on February 5, 2014)
- AGREEMENT (Filed With SEC on May 1, 2013)
- AGREEMENT (Filed With SEC on April 23, 2013)
- Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. (Filed With SEC on March 14, 2012)
- IDERA PHARMACEUTICALS, INC. (Filed With SEC on November 10, 2011)
- AMENDMENT NO. 4 TO RIGHTS AGREEMENT (Filed With SEC on November 10, 2011)
- EX-101 INSTANCE DOCUMENT (Filed With SEC on August 5, 2011)
- EX-101 INSTANCE DOCUMENT (Filed With SEC on August 5, 2011)
- EX-101 INSTANCE DOCUMENT (Filed With SEC on August 5, 2011)
- Idera Pharmaceuticals, Inc. (Filed With SEC on March 10, 2011)
- FINANCIAL STATEMENTS (Filed With SEC on August 5, 2010)
- FINANCIAL STATEMENTS (Filed With SEC on August 5, 2010)
- Rodman & Renshaw, LLC 1251 Avenue of the Americas, 20th Floor, New York, NY 10020 Tel: 212 ###-###-#### Fax: 212 ###-###-#### www.rodm.com Member: FINRA, SIPC (Filed With SEC on August 3, 2010)
- Drug candidate(s) (Filed With SEC on March 10, 2010)
- EX-10.1 Offer letter, dated November 27, 2006, as amended (Filed With SEC on November 5, 2009)
- IDERA PHARMACEUTICALS, INC. (Filed With SEC on June 10, 2008)
- IDERA PHARMACEUTICALS, INC. (Filed With SEC on June 10, 2008)
- EX-10.1 Letter Agreement dated May 17, 2007, Robert G. Andersen (Filed With SEC on August 1, 2007)
- EX-4.1 Amendment No. 3 to Rights Agreement, dated as of January 16, 2007 (Filed With SEC on January 17, 2007)
- EX-10.5 ENGAGEMENT LETTER (Filed With SEC on March 29, 2006)
- EX-4.1 AMENDMENT NO. 2 TO RIGHTS AGREEMENT (Filed With SEC on March 29, 2006)
- EX-10.7 Noteholders Agreement (Filed With SEC on August 9, 2005)
- EX-10.6 Engagement Letter (Filed With SEC on August 9, 2005)
- EX-10.3 FORM OF WARRANTS ISSUED ON AUGUST 27, 2004 (Filed With SEC on November 12, 2004)
- EX-10.1 ENGAGEMENT LETTER DATED AUGUST 27, 2004 (Filed With SEC on November 12, 2004)
